Perspective Therapeutics (CATX) Operating Income (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Operating Income data on file, last reported at -$28.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 29.54% year-over-year to -$28.3 million; the trailing twelve-month figure through Mar 2026 stood at -$113.7 million (down 14.06% YoY), and the FY2025 full-year result was -$113.6 million, down 24.95% from the prior year.
• Operating Income retreated to -$28.3 million in Q1 2026, from -$21.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$1.4 million in Q1 2022 to a low of -$45.0 million in Q4 2024.
• A 5-year average of -$14.3 million and a median of -$10.7 million in 2023 frame the typical range for Operating Income.
• Peak annual rise in Operating Income reached 26.79% in 2023, while the deepest fall reached 609.38% in 2023.
• Tracing CATX's Operating Income over 5 years: stood at -$5.6 million in 2022, then sank by 107.72% to -$11.7 million in 2023, then sank by 285.27% to -$45.0 million in 2024, then surged by 51.47% to -$21.8 million in 2025, then slipped by 29.54% to -$28.3 million in 2026.
• Business Quant data shows CATX's Operating Income at -$28.3 million in Q1 2026, -$21.8 million in Q1 2025, and -$45.0 million in Q4 2024.